Dr. Pinato on Study of Sorafenib in Pretreated Patients With HCC

David James Pinato, MD, MRCP, PhD
Published: Friday, Apr 28, 2017



David James Pinato, MD, MRCP, PhD, faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of sorafenib (Nexavar) in pretreated patients with hepatocellular carcinoma (HCC).

This was an observational study conducted to establish whether prior treatment to sorafenib was a determinant of survival in patients with HCC.

It did not matter whether the patient was in an advanced stage of the disease or intermediate, says Pinato—if they had received treatment prior to starting sorafenib, their survival was better.

According to Pinato, this study shows that the sequencing of treatment in this patient population can have an effect on survival.
 


David James Pinato, MD, MRCP, PhD, faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of sorafenib (Nexavar) in pretreated patients with hepatocellular carcinoma (HCC).

This was an observational study conducted to establish whether prior treatment to sorafenib was a determinant of survival in patients with HCC.

It did not matter whether the patient was in an advanced stage of the disease or intermediate, says Pinato—if they had received treatment prior to starting sorafenib, their survival was better.

According to Pinato, this study shows that the sequencing of treatment in this patient population can have an effect on survival.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x